Logo

Roche's Tecentriq + CT (abraxane and carboplatin) Receive the US FDA's Approval for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Share this

Roche's Tecentriq + CT (abraxane and carboplatin) Receive the US FDA's Approval for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Shots:

  • The approval is based on P-III IMpower130 study assessing Tecentriq + CT vs CT as monothx. in 681 chemotherapy-naïve patients with stage IV metastatic non-sq NSCLC with no EGFR or ALK genomic tumor aberrations
  • The P-III IMpower130 study results: OS (18.6 vs 13.9 mos.); PFS (7.2 vs 6.5 mos.); safety profile is consistent with the profile; no new safety signals were observed
  • Tecentriq is mAb targeting PD-L1 which is expressed on tumor cells and tumor-infiltrating immune cells- blocking its interactions with both PD-1 and B7.1 receptor and is approved in multiple countries including the US and EU as both monothx. and combination therapy for NSCLC and SCLC- types of m-UC and in PD-L1+ m-triple-negative BC

Click here to­ read full press release/ article 

 Ref: GlobeNewswire | Image: Roche


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions